Table 4.
Therapeutic indicator of global status: ΔCDR-SB
| Therapeutic response, N (%) | Favorablea,22 (37.9) | Poorb,36 (62.1) | p-value |
|---|---|---|---|
| Age, years (mean ± SD) | 82.1 ± 6.2 | 82.7 ± 5.3 | 0.741 |
| Education, years (mean ± SD) | 7.7 ± 5.1 | 7.9 ± 4.6 | 0.888 |
| Gender, female (%) | 14 (63.6) | 30 (83.3) | 0.089 |
| 1st CDR-SB | 8.8 ± 3.6 | 7.6 ± 3.2 | 0.207 |
| 1st MMSE | 13.8 ± 6.7 | 14.9 ± 6.1 | 0.534 |
| Cilostazol use | 0.104 | ||
| Yes | 14 (48.3) | 15 (51.7) | |
| No | 8 (27.6) | 21 (72.4) | |
| ApoE ε4(+),n (%) | 6 (31.6) | 6 (17.7) | 0.245 |
MMSE Mini-Mental Status Examination, CDR_SB Clinical Dementia Rating Sum of Boxes scale; ApoE apolipoprotein E, ΔCDR_SB: 2nd CDR_SB – 1st CDR_SB
aΔCDR_SB ≤ 0
bCDR_SB > 0